HR and Langer mesomelic dysplasia: The percentage of patients who received any systemic therapy after the diagnosis of LMD differed by subtype: HR+/HER2− (33/53, 62.3%), HER2+(22/30, 73.3%), TNBC (11/28, 39.3%).